Repligen (RGEN) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $168.53 +0.55%
Revenue Growth %: +9.4%
Financial Fact:
Net (loss) income: 1.16M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +9.4%
Financial Fact:
Net (loss) income: 1.16M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.08, in-line with the analyst estimate of $0.08. Revenue for the quarter came in at $24.7 million versus the consensus estimate of $24.39 million.
GUIDANCE:
Repligen sees FY2016 EPS of $0.42-$0.48, versus the consensus of $0.44. Repligen sees FY2016 revenue of $102-105 million, versus the consensus of $104.0 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Braze stock tumbles 10% on weak third quarter EPS guidance
- Mission Produce (AVO) Misses Q3 EPS by 2c; offers outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
